The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
In patients with mostly undifferentiated pleomorphic sarcomas, 2-year DFS with the addition of preoperative and postoperative pembrolizumab (Keytruda) infusions reached 67%, as compared with 52% with ...
Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A 56-year-old man presented to the ED with 3 months of ...
— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with ...
Please provide your email address to receive an email when new articles are posted on . A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ...
In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas. Liposarcomas originate in fat cells and ...
(RTTNews) - Intensity Therapeutics, Inc. (INTS), a late-stage clinical biotechnology company focused on immune-based cancer therapies, announced Tuesday that its INVINCIBLE-3 Study has been authorized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback